Vertex Pharmaceuticals (VRTX): Takeaways from ASN on emerging kidney franchise

Full Pove Ph3 IgAN data were published in NEJM and VRTX hosted an analyst event at the ASN conference. The full data were in line with the top line data, and VRTX expressed confidence on approval/label heading into the 11/30 PDUFA date. We reiterate our OW rating. In our opinion, the full Ph3 IgAN data for Pove (APRIL/BAFF dual inhibitor) were in line with the prior top line release and there were no surprises. There was no new safety signal (e.g., infection or hypogamma), and while anti-drug antibodies (ADAs) were observed, they had no impact on efficacy or the risk profile per the company. VRTX expressed confidence in approval ahead of the Nov 30 PDUFA date and that the label will not have any different monitoring requirements relative to approved competitor drugs - Otsuka's Voyxact and VERA's Trutakna. The Pove Ph3 IgAN data continue to support a highly competitive profile, taking into consideration efficacy, safety, Q4W dosing and low-volume autoinjector delivery. As disclosed in t